From the ∗Department of Rheumatology, Hospital Can Misses, Ibiza
†Department of Rheumatology, Hospital Universitario La Princesa, IIS-Princesa, and Cátedra UAM-Roche, EPID-Futuro, Universidad Autónoma de Madrid (UAM)
‡Institute for Musculoskeletal Health
§Department of Rheumatology, Hospital Universitario La Paz, IdiPAZ
∥Research Unit, Spanish Society of Rheumatology, Madrid
¶University of Cantabria. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander
#Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain
∗∗University of the Witwatersrand, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, South Africa.
The project was funded with an independent grant from UCB Pharma.
E.L. has received grants from Pfizer, Abbvie, Novartis, Roche, UCB, Sanofi, BMS, Lilly, MSD, and Janssen. The other authors declare no conflict of interest.
Correspondence: Ana Urruticoechea-Arana, MD, PhD, Rheumatology Unit Hospital, Can Misses Carrer de Corona, s/n 07800 Ibiza, Spain. E-mail: [email protected].
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.jclinrheum.com).
